<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo





                              August 31, 2022

       Thomas M. Herzog
       Chief Executive Officer
       Healthpeak Properties, Inc.
       5050 South Syracuse Street, Suite 800
       Denver, Colorado 80237

                                                        Re: Healthpeak
Properties, Inc.
                                                            Definitive Proxy
Statement on Schedule 14A
                                                            Filed March 17,
2022
                                                            File No. 001-08895

       Dear Mr. Herzog:

             We have limited our review of your most recent definitive proxy
statement to those issues
       we have addressed in our comments.

               Please respond to these comments by confirming that you will
enhance your future proxy
       disclosures in accordance with the topics discussed below as well as any
material developments
       to your risk oversight structure. For guidance, refer to Item 407(h) of
Regulation S-K

       Definitive Proxy Statement on Schedule 14A filed March 17, 2022

       General

   1.                                                   Please expand your
discussion of the reasons you believe that your leadership structure is
                                                        appropriate, addressing
your specific characteristics or circumstances. In your discussion,
                                                        please also address the
circumstances under which you would consider having the Chair
                                                        and CEO roles filled by
a single individual, when shareholders would be notified of any
                                                        such change, and
whether you will seek prior input from shareholders.
   2.                                                   Please expand upon the
role that your Independent Chairman plays in the leadership of the
                                                        board. For example,
please enhance your disclosure to address whether or not your
                                                        Independent Chairman
may:

                                                              represent the
board in communications with shareholders and other stakeholders; or
                                                              require board
consideration of, and/or override your CEO on, any risk matters.
   3.                                                   Please expand upon how
your board administers its risk oversight function. For example,
                                                        please disclose:
 Thomas M. Herzog
Healthpeak Properties, Inc.
August 31, 2022
Page 2
                the timeframe over which you evaluate risks (e.g., short-term,
intermediate-term, or
              long-term) and how you apply different oversight standards based
upon the
              immediacy of the risk assessed;
                whether you consult with outside advisors and experts to
anticipate future threats and
              trends, and how often you re-assess your risk environment;
                how the board interacts with management to address existing
risks and identify
              significant emerging risks;
                whether you have a Chief Compliance Officer and to whom this
position reports; and
                how your risk oversight process aligns with your disclosure
controls and procedures.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Please contact Jennifer Gowetski at 202-551-3401 or Amanda Ravitz at
202-551-
3412 with any questions.



FirstName LastNameThomas M. Herzog                             Sincerely,
Comapany NameHealthpeak Properties, Inc.
                                                               Division of
Corporation Finance
August 31, 2022 Page 2                                         Disclosure
Review Program
FirstName LastName
</TEXT>
</DOCUMENT>
